

How to Cite:

Al terkawi, M. M. (2023). Evaluation of total tumor volume reduction ratio in initially unresectable colorectal liver metastases after first line treatment. *International Journal of Health Sciences*, 7(S1), 2322–2327. <https://doi.org/10.53730/ijhs.v7nS1.14489>

Evaluation of total tumor volume reduction ratio in initially unresectable colorectal liver metastases after first line treatment

Dr Madian Mohamed Al terkawi

Radiologist Work in Saudi German hospital Dubai

Corresponding author email: madianterkawi@hotmail.com

Abstract---Background: Total tumour volume is predictive factor for hepatic resection in some solid tumours, but its significance in colorectal liver metastases has not been fully investigated. liver is most frequent location of distant metastasis for colorectal cancer, which is 1 of most common cancers to cause cancer-related deaths globally. For colorectal liver metastases, hepatic resection is widely recognized as most effective therapy & only possibly curative operation. assessment of tumour burden can depend significantly on total tumour volume. Aim: In this review, we sought to assess the total tumour volume decrease ratio in colorectal liver metastases that were initially unresectable following 1st-line therapy, Summary: After receiving 1st-line systemic therapy, decreased ratio of TTV had been reliable predictor of conversion result & long-term prognosis in studied cases with originally unresectable CRLM.

Keywords---colorectal liver metastases, conversion therapy, total tumor volume, reduction ratio.

Introduction

3rd most prevalent cancer in world, colorectal cancer, has significant mortality rate. Throughout course of illness, CRC liver metastasis occurs in about thirty to fifty percent of individuals. main curative option for single CRLM is liver resection, which has twenty to fifty percent five-year survival rate. But 1st-line chemotherapy, such as 5-fluorouracil, leucovorin, oxaliplatin, or irinotecan, is necessary for majority of CRLM studied cases. When compared to 1st-line chemotherapy, use of targeted medicines like anti-vascular endothelial growth factor (bevacizumab) & anti-epidermal growth factor receptor (cetuximab or panitumumab) monoclonal antibodies has increased survival. In making clinical treatment decisions, early evaluation of bevacizumab chemotherapy's effectiveness may be useful (1).

Size criteria, most frequently Response Evaluation Criteria in Solid Tumours, are used to evaluate response to treatment. Because of cytostatic action of bevacizumab, nevertheless, size-based RECIST v1.1 cannot appropriate for early assessment of effectiveness of bevacizumab for treatment of CRLM. nonsurgical patient cohort was used to validate 2009 morphological assessment criteria for CRLM used to evaluate response to antiangiogenic therapy in preoperative scenario. These parameters had been linked to better long-term prognosis, according to later investigations. This criterion states that crucial foundation for response therapy is CRLM shifting from heterogeneous masses with ill-defined margins into homogenous hypoattenuating lesions with sharp borders after bevacizumab treatment (2).

Additionally, by examining enhanced area in arterial phase of lesion, m-RECIT criteria are frequently used to assess effectiveness of targeted therapy for liver tumours. These criteria were generated from naked-eye observations, although their application & reproducibility are currently limited. Additionally, research from additional centers needs to confirm radiological aspects of morphological criterion. Radiomics, novel image analysis technique, is applied to assess impact of treatment on CRLM. Yet, due to its laborious, labor-intensive, & imperfectly reproducible nature, this procedure has limited utility in clinical use (3).

In early response evaluation of treatment for CRLM, number of quantitative imaging techniques, including F18-fluorodeoxyglucose PET/CT & diffusion-weighted magnetic resonance imaging, have demonstrated good performance. Yet, high expense of MRI & PET/CT limits their usage in majority of studied cases with CRLM since individuals with CRLM require numerous imaging tests. Multiparametric spectral CT, new imaging technique, is frequently employed to assess liver conditions. This approach is frequently utilized in clinical practice because of its multiparametric imaging properties, which allow it to assess tumour cell proliferation, micro vessel density, & fibre structure. Additionally, early post-chemotherapy bevacizumab generated drop in iodine concentration but did not result in smaller lesion. nevertheless, there are no reports of using multiparametric spectral CT to evaluate effectiveness of 1st-line chemotherapy in CRLM studied cases that includes bevacizumab-containing therapy (4).

For studied cases with CRLM, early assessment of effectiveness of 1st-line chemotherapy in combination with bevacizumab is essential for enhancing studied case outcomes. IoD had been identified as independent predictor of R + in 2-month portal venous phase spectral CT scan for early quantitative assessment of FOLFOXIRI and bevacizumab efficacy in studied cases with CRLM. Following treatment for CRLM, IoD, baseline CEA, BLD, K-RAS mutation, & metachronous liver metastases had been independent risk factors for OS. Yet, there had been no statistically significant relationships with OS in studied cases with CRLM according to 2-RECIST v1.1. With AUC of 0.916, sensitivity & specificity of 80.3percent & 96.4percent, & positive & negative predictive values of 0.984 & 0.643, respectively, IoD also demonstrated strong discriminative performance for R as described by 6-RECIST v1.1. These findings suggested that in CRLM studied cases treated with FOLFOXIRI coupled with bevacizumab within two months of starting treatment, IoD on portal venous phase spectral CT may represent therapeutic success (5).

In CRLM studied cases, K-RAS mutations are related negatively to OS. As result of 1st-line chemotherapy plus bevacizumab in studied cases with CRLM, our findings showed that K-RAS mutation had been independent predictor of OS. varying responses to systemic chemotherapy depending on presence or absence of K-RAS mutation may be cause. examined relationship among RAS mutational status & preoperative chemotherapy response in studied cases with CRLM in setting of systemic chemotherapy. Significantly, minor pathogenic & poor morphological responses had been related to RAS mutations. In studied cases with CRLM, K-RAS mutations had been substantially related to minimal response to chemotherapy, & presence or absence of RAS mutations can be biomarker for chemotherapy response (6).

Additional risk factors for OS after FOLFOXIRI coupled with bevacizumab for CRLM had been greater baseline CEA (≥ 31.7 ng/mL), BLD, & metachronous liver metastases. We think that initial extent of liver metastases influences how deeply chemotherapeutic medicines enter tumour. Additionally, prior research has demonstrated that significant prognostic markers of CRLM include size of liver metastases at baseline & size of metastases at 1st follow-up. For studied cases with substantial baseline (≥ 25.77 mm) liver metastases, systemic therapy must be coupled with transcatheter arterial chemoembolization or radiofrequency ablation to increase long-term survival. Additionally, univariate analysis confirmed multiple earlier studies in CRLM by demonstrating association between OS of CRLM & initial tumor's histologic grade, T stage, & N stage (7).

Spectral CT has variety of imaging parameters, such as base material & single-energy CT imaging, compared to conventional mixed-energy CT. IoD may reflect density of tumour microvessels, according to earlier investigations. Due to absence of typical arterial wall composition in tumour microvessels, iodine is retained or extravasates into tumour. early prediction of effectiveness of targeted therapy for metastatic renal cell cancer using dual-energy CT IoD. IoD at beginning of chemotherapy & one month later had been separate risk factors for results in studied cases with mRCC. Additionally, following surgery, NIoD may forecast early return of hepatocellular carcinoma. According to histopathological investigation, microvessel density and NIoD were strongly associated with hepatocellular carcinoma. Thus, variation in NIoD represents effectiveness of therapy. In studied cases with CRLM, IoD within two months of treatment posed independent risk factors for OS (8).

In univariate analysis, there had been also correlation among lower CS & OS, & CRLM. increased IOD [≥ 4.75 (100ug/cm³)] in CRLM following administration of FOLFOXIRI in combination with bevacizumab suggests that tumor's microvascular network is not sufficiently inhibited or eliminated. Thus, multivariate logistic regression indicated that IoD had been independent predictor of CRLM. results of several earlier research, nevertheless, seem to indicate that survival outcomes in studied cases with CRLM are not predicted by baseline & post-treatment CT characteristics. For noninvasively predicting early efficacy responses & survival outcomes in studied cases with CRLM, spectral CT characteristics can be valuable biomarker (9).

liver is most common site for metastases in colorectal cancer, affecting twenty percent to fifty percent of studied cases as disease progresses & fifteen percent to twenty percent of newly diagnosed CRC cases. When aiming for curation, surgery, & ablation continue to be primary options. Resection rates of metastatic CRC in multimodal approaches currently reach fifty percent in specialized centers as result of the use of progressive oncosurgical procedures. To ensure respectability while keeping adequate future liver volume, advanced colorectal liver metastases must be reduced in size before to surgery using preoperative combination chemotherapy (preopCTX). In subgroup of studied cases with primary resectable illness but unfavourable tumour features, evidence also points to benefit of preopCTX. Through chemotherapy-related liver impairment, prolonged preopCTX is linked to significant toxicity & raises postoperative morbidity & death. Guidelines advise limiting preoperative treatment to three months or fewer in order to prevent problems; as result, early radiological response assessment is essential (10).

According to response evaluation criteria in solid tumours, response is typically categorized at moment of maximum tumour decrease. Although benefits for objective, standardized testing, this classification implies number of restrictions. RECIST stable disease subgroup is criticized for includes instances with both modest tumour shrinkage (zero percent-twenty nine percent size reduction) & minor tumour advancement (one percent-nineteen size increase), in addition to necessity of unavoidable radiological expertise & time-consuming application. Additionally, studied cases with complete response or progressive disease are infrequently represented in conventional surgical CRLM cohorts, which restricts clinical practice's ability to reasonably stratify studied cases' risks. Recent trials examining 1st-line CTX in mCRC have looked at early tumour shrinkage as straightforward measure for treatment guidance following 1st restaging to promote early restaging (7).

While there isn't clear definition yet, ETS is typically evaluated 6–12 weeks after CTX is started & is characterized as minimum of $\geq$ twenty to thirty percent size reduction in target lesions' diameters. In these trials, ETS is linked to better progression-free survival & overall survival. application of these findings in CRLM studied cases receiving CTX in prospective preoperative scenario is uncertain because resectability rates in 1st-line CTX studies typically range below fifteen percent & because ETS is not yet confirmed in purely surgical cohort. Additionally, prior single-center study demonstrated that morphological criteria with evaluation of changes in radiological CRLM appearance (tumour density, tumor-liver border) outperform size-based criteria like RECIST in predicting histological viability & prognosis after liver resection. Yet, as response had been assessed after median of six (up to twenty-four) cycles of CTX, it is uncertain if it would be transferable to contemporary situation of brief preoperative treatment with earliest possible restaging (10).

Size-based criteria like RECIST or ETS do not accurately correlate with pathological response as do morphology-based criteria like MC. fact that our cohort's MC response had not been substantially correlated with OS, however, is surprising given that prior studies have only consistently demonstrated correlation when larger cohorts (>two hundred studied cases) had

been analyzed. This is likely due to small number of studied cases that had ideal MC response. Several devoted hepatobiliary surgeons who have been treating advanced CRLM with oncosurgery over past few years have questioned usefulness of strictly size-based response criteria like RECIST to accurately determine studied cases who will benefit from resection following preopCTX. It's intriguing to note that, to best of our knowledge, this research is 1st to present evidence indicating that combined application of size-& morphology-based criteria can allow for more accurate stratification of cellular response & subsequently anticipated postoperative survival. After median of sixty-two days, our research found that combination of ETS & MC was powerful predictor of pathological response & survival (12).

studied cases who do not meet either of 2response criteria only sometimes exhibit major pathological response, & their chances of long-term survival are dismal, with estimated 5-year OS rates of just <twenty percent & five-year DFS rates of just <ten percent. five-year OS & DFS in cases with both ETS & optimum MC response, however, are greater than sixty percent & thirty percent, respectively, with stunning ninety two percent experiencing major or total pathological response. Additionally, multivariable analysis has validated independent relationship between combined ETS/MC criterion & OS following resection, even after adjusting for other recognised risk factors such initial tumor's nodal positivity & RAS mutation or requirement for significant liver resections (8).

Importantly, it is simple to use combined ETS/MC criteria in clinical practise. It takes very little radiological expertise & time to evaluate up to 2 target liver lesions for twenty percent decrease in their overall diameter & existence of homogenous & hypoattenuating appearance with well-defined, sharp tumor-liver interface during restaging. Although MC grading process had been somewhat subjective, there had been previously shown to be good interobserver agreement amongst various radiologists, ensuring acceptable validity. Contrarily, it is important to acknowledge the clinical limits of RECIST assessment. Time-consuming RECIST grading yields 4 subgroups, of which 1 (SD) is criticized for its cut-off ranges & 2 (CR & PD) are of little therapeutic utility because of their uncommon incidence in contemporary neoadjuvant CRLM treatment. Additionally, prior research has shown that RECIST is less accurate than MC at predicting pathological response & OS in studied cases receiving preopCTX for CRLM that contains bevacizumab. (13).

References

1. Robles-Campos, R., Lopez-Lopez, V., Brusadin, R., Lopez-Conesa, A., Gil-Vazquez, P. J., Navarro-Barrios, Á., et al. (2019). Open versus minimally invasive liver surgery for colorectal liver metastases (LapOpHuva): a prospective randomized controlled trial. *Surgical Endoscopy*, 33, 3926–3936.
2. Mulcahy, M. F., Mahvash, A., Pracht, M., Montazeri, A. H., Bandula, S., Martin, R. C. G., et al. (2021). Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. *Journal of Clinical Oncology*, 39(35), 3897–3907.
3. Syn, N. L., Kabir, T., Koh, Y. X., Tan, H. L., Wang, L. Z., Chin, B. Z., et al.

- (2020). Survival advantage of laparoscopic versus open resection for colorectal liver metastases: a meta-analysis of individual patient data from randomized trials and propensity-score matched studies. *Annals of Surgery*, 272(2), 253–265.
4. Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., et al. (2020). Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. *International Journal of Clinical Oncology*, 25, 1–42.
 5. Takahashi, H., Berber, E. (2020). Role of thermal ablation in the management of colorectal liver metastasis. *Hepatobiliary Surgery and Nutrition*, 9(1), 49.
 6. Edhemovic, I., Brecelj, E., Cemazar, M., Boc, N., Trotovsek, B., Djokic, M., et al. (2020). Intraoperative electrochemotherapy of colorectal liver metastases: a prospective phase II study. *European Journal of Surgical Oncology*, 46(9), 1628–1633.
 7. Bonney, G. K., Chew, C. A., Lodge, P., Hubbard, J., Halazun, K. J., Trunecka, P., et al. (2021). Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. *The Lancet Gastroenterology & Hepatology*, 6(11), 933–946.
 8. Oki, E., Emi, Y., Yamanaka, T., Uetake, H., Muro, K., Takahashi, T., et al. (2019). Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). *British Journal of Cancer*, 121(3), 222–229.
 9. Mao, Y., Chen, B., Wang, H., Zhang, Y., Yi, X., Liao, W., et al. (2020). Diagnostic performance of magnetic resonance imaging for colorectal liver metastasis: A systematic review and meta-analysis. *Scientific Reports*, 10(1), 1969.
 10. Moris, D., Tsilimigras, D. I., Machairas, N., Merath, K., Cerullo, M., Hasemaki, N., et al. (2019). Laparoscopic synchronous resection of colorectal cancer and liver metastases: a systematic review. *Journal of Surgical Oncology*, 119(1), 30–39.
 11. Jensen, C. T., Wagner-Bartak, N. A., Vu, L. N., Liu, X., Raval, B., Martinez, D., et al. (2019). Detection of colorectal hepatic metastases is superior at standard radiation dose CT versus reduced dose CT. *Radiology*, 290(2), 400–409.
 12. Imai, K., Adam, R., Baba, H. (2019). How to increase the resectability of initially unresectable colorectal liver metastases: A surgical perspective. *Annals of Gastroenterological Surgery*, 3(5), 476–486.
 13. He, J., Li, W., Zhou, J., Sun, H., Zhou, C., Liu, Y., et al. (2023). Evaluation of total tumor volume reduction ratio in initially unresectable colorectal liver metastases after first-line systemic treatment. *European Journal of Radiology*, 110950.